Edition:
United Kingdom

FibroGen Inc (FGEN.OQ)

FGEN.OQ on NASDAQ Stock Exchange Global Select Market

53.55USD
5:07pm BST
Change (% chg)

$0.10 (+0.19%)
Prev Close
$53.45
Open
$53.10
Day's High
$54.00
Day's Low
$53.05
Volume
20,145
Avg. Vol
195,910
52-wk High
$63.00
52-wk Low
$25.40

Latest Key Developments (Source: Significant Developments)

Fibrogen Inc reports Q3 loss per share $0.50
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Fibrogen Inc ::Fibrogen reports third quarter 2017 financial results.Q3 loss per share $0.50.Q3 earnings per share view $-0.37 -- Thomson Reuters I/B/E/S.nda filing for roxadustat for anemia in​ ckd with u.s. Food and drug administration targeted for 2018.qtrly ‍total revenue $27.3 million versus $30.1 million.  Full Article

Fibrogen announces acceptance by china FDA of roxadustat NDA for treatment of anemia associated with dialysis and non-dialysis kidney disease
Wednesday, 18 Oct 2017 

Oct 18 (Reuters) - Fibrogen Inc :Fibrogen announces acceptance by china FDA of roxadustat new drug application (NDA) for treatment of anemia associated with dialysis and non-dialysis chronic kidney disease (CKD).Fibrogen - ‍under terms of Fibrogen's agreement with Astrazeneca, NDA submission triggers a $15 million milestone payment, payable to co by Astrazeneca​.  Full Article

Fibrogen reports Q2 EPS of $0.39
Monday, 8 Aug 2016 

Fibrogen Inc : Fibrogen reports financial results for the second quarter of 2016 . Q2 earnings per share $0.39 . Q2 earnings per share view $0.36 -- Thomson Reuters I/B/E/S . Qtrly total revenue $89.3 million versus $120.6 million .Q2 revenue view $78.5 million -- Thomson Reuters I/B/E/S.  Full Article

Fibrogen announces receipt of $62 million license payment from Astrazeneca
Friday, 8 Jul 2016 

Fibrogen Inc : Fibrogen announces receipt of $62 million license payment from Astrazeneca .Astrazeneca,Co collaborating on development,commercialization of drug for treatment of Anemia in patients with CKD in U.S., China, other markets.  Full Article

BRIEF-FibroGen Reports Q1 Loss Per Share $0.50

* Q1 EARNINGS PER SHARE VIEW $-0.51 -- THOMSON REUTERS I/B/E/S